Sarcoidosis - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Sarcoidosis Market Outlook

Thelansis's "Sarcoidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sarcoidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Sarcoidosis Overview

Sarcoidosis is a chronic, multisystem inflammatory disorder characterized by the formation of non-caseating granulomas in affected organs, driven by dysregulated immune responses in genetically susceptible individuals. The disease most commonly affects the lungs and intrathoracic lymph nodes, although extrapulmonary involvement frequently occurs in the skin, eyes, heart, liver, and nervous system. Clinical presentation is highly variable, ranging from asymptomatic disease to chronic progressive organ dysfunction associated with dyspnoea, persistent cough, fatigue, and organ-specific complications.

Diagnosis is based on a combination of clinical, radiological, and histopathological findings, including imaging evidence of bilateral hilar lymphadenopathy and biopsy-confirmed non-caseating granulomas while excluding infectious and malignant causes. Corticosteroids remain the mainstay of therapy for symptomatic or progressive disease, while immunosuppressive agents such as methotrexate and azathioprine are commonly used as steroid-sparing therapies. Refractory or severe disease may require biologic therapies, including anti-TNF agents such as infliximab.

Despite spontaneous remission in some patients, a substantial proportion develop chronic or progressive disease requiring long-term monitoring and multidisciplinary management. Persistent fatigue, pulmonary fibrosis, cardiac involvement, and treatment-related toxicity continue to represent significant unmet clinical challenges. The evolving treatment landscape is increasingly focused on targeted immunomodulatory therapies and improved long-term disease management strategies.

Key Highlights

• In France, sarcoidosis prevalence cases are projected to increase from approximately 22,210 in 2025 to nearly 23,815 by 2035, reflecting a gradual increase in disease burden.
• Pulmonary sarcoidosis remains the predominant clinical presentation, accounting for the majority of diagnosed cases.
• Chronic progressive disease and extrapulmonary involvement continue to contribute significantly to long-term morbidity.
• Corticosteroids remain the standard of care; however, long-term steroid toxicity drives increasing use of steroid-sparing immunosuppressive therapies.
• Growing interest in targeted biologic therapies is expanding treatment options for refractory and severe sarcoidosis cases.

Market Overview

• The France sarcoidosis market is projected to grow from approximately $22 MN to $55 MN by 2035, reflecting notable market expansion.
• Market growth is supported by:
• Increasing use of immunosuppressive and biologic therapies in chronic disease management
• Improved diagnosis and long-term monitoring of multisystem disease involvement
• Market value growth is driven by prolonged treatment duration and increasing adoption of advanced therapies in refractory disease.
• Future growth will depend on development of targeted immunomodulatory therapies and improved management strategies for chronic progressive sarcoidosis.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country